AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker ...

British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in the Chinese capital.

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Syneron Bio has partnered with AstraZeneca to develop potential first-in-class macrocyclic peptides for the treatment of ...

Angle announced on Friday the successful completion of assay development projects for AstraZeneca and Eisai, further ...

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why AZN stock is a Buy.

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...

In this article, we are going to take a look at where AstraZeneca ... all new prescriptions were for it. Tirzepatide, Liraglutide, and Semaglutide are the only three GLP-1 weight-control drugs ...

AstraZeneca missed fourth-quarter estimates for earnings but beat the same for sales. Revenues increased across all segments, with sales of most of the key drugs, including Tagrisso, Fasenra ...

AstraZeneca has enlisted the help of Lilly in the development of its new Alzheimer's candidate AZD3293. The drug is an oral beta ... and the companies will share all costs equally for the ...